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Abstract
Background: Although many studies have modelled the national burdens of hospitalizations and deaths due to
influenza, few studies have considered the outpatient burden. To fill this gap for the United States (US), we applied
traditional statistical modelling approaches to time series derived from large medical claims databases held in the
private sector.
Methods: We accessed ICD-9-coded office visit data extracted from Truven Health Analytics’ MarketScan
Commercial database covering about one third of the US population <65 years during 2001–2009, and Medicare
Supplemental data covering about one fifth of US seniors 65+ during 2006–2009. We extracted weekly time series
of visits due to respiratory diagnoses, otitis media (OM), and urinary tract infections (UTI), a “negative control”. We
used multiple linear regression modelling to estimate age-specific influenza-related excess in office visits.
Results: In the <65 year age group, in the 8 pre-pandemic seasons studied and for the broadest defined respiratory
outcome, the model attributed an average of ~14.5 M (Standard deviation [SD] across seasons 3.9 million) office
visits to influenza (rate of 5,581/100,000 population). Of these, ~80 % of visits occurred in the 5–17 and 18–49 age
group. In school children aged 5–17 year olds and adult 18–64 year age groups the majority of visits were due to
influenza B, while A/H3N2 explained most visits in children <5 year olds. The model further attributed ~2.2 M OM
visits (SD across seasons 790,000) annually to influenza, of which 86 % of these occurred in children <18 years; this
indicates that 6.4 % of all infants <2 years and 4.9 % of all toddlers aged 2–4 years in the US have an influenza-
attributable outpatient visit with an OM diagnosis. In seniors 65 years and older, our model attributed ~0.7 M (SD
across seasons 351,000) respiratory visits to influenza (rate of 1,887/100,000 population). The model identified no
significant excess UTI (negative control) visits in most seasons.
Conclusions: This is to our knowledge a first study of the outpatient burden of influenza in the US in a large
database. The model estimated that 10 % of all children <18 years and 4 % of the entire population <65 years seek
outpatient care for respiratory illness attributable to influenza annually.
Trial registration: ClinicalTrial.gov, NCT02019732.
Keywords: General practice, Influenza, Burden of disease, Mathematical model
* Correspondence: goncalo.x.matias@gsk.com
1GSK Vaccines, Avenue Fleming 20, Parc de la Noire Epine, Wavre, Belgium
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Matias et al. BMC Infectious Diseases  (2016) 16:641 
DOI 10.1186/s12879-016-1939-7
Background
The true burden of influenza is difficult to measure be-
cause many infections cause influenza-like-illness and
so laboratory testing is needed to confirm influenza,
testing of patients is usually at the discretion of the
physician so that many influenza infections will not be
recorded in clinical databases, and the clinical manifes-
tations of influenza vary in adults and children, which
means that influenza may not be suspected [1, 2]. Be-
cause of these difficulties, epidemiologists use indirect
statistical approaches to attribute to influenza a portion
of seasonal increases in adverse health outcomes that
occur during influenza epidemics. These indirect statis-
tical approaches have often been used to estimate the
burden of mortality and hospitalisation [3–6]. However,
few studies have attempted to quantify the influenza
burden in the primary care setting [6–8].
Influenza causes a range of clinical symptoms that are
not confined to the respiratory tract, such as gastro-
intestinal symptoms and febrile convulsions in young
children, and sometimes the clinical illness is not
particularly severe [9]. For these reasons, influenza is
often not properly diagnosed. Otitis media (OM) often
prompts young children to consult a physician, and is
considered to be a complication of influenza infection
[2, 10]. In a recent evaluation of the influenza primary
healthcare burden in the United Kingdom (UK),
indirect modelling suggested that OM attributable to
influenza occurred in children at a similar rate to
influenza-like-illness, suggesting that rather than being
a complication of influenza, OM is part of the clinical
symptomatology of influenza in children [8].
The outpatient burden is important because it rep-
resents a substantial portion of the economic health-
care burden caused by influenza; that burden also
includes absenteeism due to illness among both adults
and their children, so that the full burden of paediat-
ric influenza extends beyond children themselves.
Estimates of the influenza burden that are limited to
respiratory outcomes, such as influenza-like-illness or
acute respiratory infection, will not capture the con-
tribution of non-respiratory diseases causes by influ-
enza, such as OM in children. We used retrospective
data extracted from MarketScan databases in a time
series model to estimate the burden of influenza-
attributable physician office visits in the United States
(US) by age, influenza strain and season (www.clini-
caltrials.gov NCT02019732). We report on a new out-
come, ‘respiratory disease broadly defined’, that
combined all respiratory diagnoses with selected pre-
senting symptoms, which was designed to have high
sensitivity while maintaining specificity compared to




Multiple linear regression models were used to quantify
the burden of multiple mild outcomes (i.e., those that re-
sult in visits to a physician’s office) attributable to influ-
enza in the US, stratifying by age and controlling for the
contribution of respiratory syncytial virus (RSV).
We included all physician office visits for a) persons
<65 years of age with an outcome of interest recorded in
the MarketScan Commercial database in the period from
July 2001 through March 2009 (eight seasons), and b) per-
sons 65+ years of age with an outcome of interest that
were recorded in the MarketScan Medicare Supplemental
database in the period from July 2006 through March
2009 (three seasons). Data from individual subjects were
not linked over time.
The study was conducted according to International So-
ciety for Pharmacoepidemiology Guidelines for Good
Pharmacoepidemiology Practices, local regulations and
privacy laws. Consent was not needed as all patients were
anonymised and only aggregate data are reported here.
Data sources
The MarketScan databases used in this study are main-
tained by Truven Health Analytics (formerly Thomson
Medstat), and contain claims data from a variety of health
plans [11]. The gender, age, and geographic distribution of
the MarketScan population can be weighted to create na-
tionally representative samples of Americans covered by
health insurance. At the time of the study the databases
covered 110.1 million persons <65 years of age and 6.4
million persons aged 65+ years. It should be noted that
the two datasets were different and any comparison of the
two sets of estimates should be made cautiously.
Weekly influenza surveillance data were obtained from
the Centers for Disease Control and Prevention (CDC)
[12]. Influenza virology data were collected for weeks 40
of the first year in a season through week 20 in the second
year, by approximately 80 US World Health Organization
collaborating laboratories and 60 National Respiratory and
Enteric Virus Surveillance Systems (NREVSS) laboratories.
Weekly RSV surveillance data were obtained from the
NREVSS [13].
Data preparation
We defined several outcomes of varying sensitivity and
specificity using International Classification of Disease
(ICD)-9 codes (Table 1). We developed an outcome cat-
egory ‘respiratory disease broadly defined’ that included
diseases of the respiratory system as well as fever, cough,
abnormalities of breathing and unspecified viral
infections. A negative control outcome (urinary tract
infection) was used to assess the presence of trends not
associated with influenza.
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For each outcome we extracted weekly time series,
stratified by age group and region, of the total number
of physician office visits recorded during the week di-
vided by the total of covered persons during the same
week; records with any mention of defined codes among
the recorded diagnoses were included. Weighting factors
based on regional populations of age groups were used
to remove substantial year-to-year changes in covered
populations that occurred each January.
The influenza virology time series were given by the
total number of positives by type and subtype, divided
by the seasonal total number of influenza tests. The RSV
virology time series were given by the number of posi-
tives divided by the seasonal total number of RSV tests.
The time series for each outcome were stratified by age
group. These were merged into the database of weekly
outcome time series, by week and year, and employed as
explanatory variables.
Statistical methods
Each age group and region outcome series was modelled
by multiple regression. Numbers of influenza-attributable
outcome cases were summed across regions, and con-
verted to national rates. Seasonal 95 % confidence inter-
vals (CI) were computed based on the standard error of
the multiple regression model parameter for each individ-
ual pathogen. We calculated the weekly point estimates as
the product of the regression coefficient and the weekly
viral circulation, then aggregated the weekly estimates
over the entire season. We repeated the procedure using
the lower and upper 95 % estimates for the regression par-
ameter to obtain the seasonal upper and lower CIs.
The variability of seasonal all-age estimates was assessed
using standard deviations (SD). This SD represents the
variability of the attributable burden between seasons and
not the uncertainty of the individual seasonal estimates.
The best model fit for both databases adjusted for major
holidays using a dummy variable approach. Cyclic terms
(sine and cosine with annual period) and lagging of the
virology series were considered but not used in the best-fit
models. The use of sine and cosine terms to model sea-
sonal variations in disease incidence and disease burden is
pervasive in the literature over many decades, made ne-
cessary by the absence of data to model seasonal variation
in incidence rates. It is intended to capture the effect of
“other pathogens” and “other factors” such as weather.
The use of sine and cosine terms is intended to capture
the effect of “other pathogens” and “other factors” such as
weather in seasonal variations in disease incidence and
disease burden. In our initial model, cyclic terms captured
a high fraction of the attribution rates across defined out-
comes. As a result, the attribution rates assigned to other
terms in the model (RSV and influenza virology indica-
tors) tended to be much smaller (and often negative) than
attribution rates captured by the cyclic terms. On remov-
ing cyclic terms from the model, negative attributions
were dramatically diminished.
The final model form for the MarketScan Commercial
Database was:
Y ¼ β1 þ β2  RSVð Þ þ β3  A=H1N1ð Þ þ β4
 A=H3N2ð Þ þ β5  Bð Þ þ β6t þ β7t2 þ β8t3
where t is the week number, Y is the incidence of an
outcome in each time period t, RSV & influenza (A/
H1N1, A/H3N2 and B) are the proportions of laboratory
isolates during t.
Medicare Supplemental data were limited to three sea-
sons. Collinearity amongst the various virus terms re-
sulted in unstable results and poor fits. We therefore
aggregated the influenza terms (A/H1N1, A/H3N2 and
B) into a single influenza term in the model; we then
made seasonal attributions to each type/subtype accord-
ing to the seasonal proportion of positive samples. The
final model form was:
Y ¼ β1 þ β2  RSVð Þ þ β3  Aggregated Influenzað Þ
þ β4t þ β5t2 þ β6t3
Statistical analyses were performed using SAS 9.3.
Results
Model fit
The model fit (R2) for physician visits for respiratory dis-
ease (broadly defined) ranged from 0.54 to 0.79 in the
MarketScan Commercial dataset, and from 0.55 to 0.80
in the Medicare Supplemental dataset. The addition of
the virology terms to the model increased R2 in all
strata, by amounts ranging from 0.29 to 0.70. Figure 1
shows example attributions and model fit to the data.
Between 2001 and 2009, there was an average of 150
million physician visits per season for a respiratory ill-
ness (broadly defined) by individuals aged <65 year olds
in the US. Of these, an estimated 14.5 million visits
(9.6 %) (SD across seasons 3.9 million) were attributable
to influenza (Table 2); of which 1.7 % were attributed to
influenza A/H1N1, 3.9 % to influenza A/H3N2 and
Table 1 Outcomes of interest
Description ICD-9-CM
Respiratory Disease Broadly Defined:
Respiratory diseases, fever, cough,







Urinary Tract Infection 599.0
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Fig. 1 Attribution modelling showing excess office visits attributable to influenza A/H1N1 (purple), A/H3N2 (orange) and B (green) in 5–17 year
olds (MarketScan Commercial Database), and influenza of all types (green) in 65–74 year olds (MarketScan Medicare Supplemental Database). The
sum of the secular trend and RSV attribution is shown in blue; the solid lines represent the observed number of respiratory (broadly defined) visits
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4.1 % to influenza B. Assuming one office visit per
individual, the data correspond to an average of 5.6 pri-
mary care visits for respiratory disease per 100 persons
aged <65 years annually.
The seasonal average rate of influenza-attributable office
visits was highest among children in age groups <18 years
(Table 3). Influenza A disease appeared to be less common
after age 17 years and decreased further with age. This
trend was less marked for influenza B; with high rates of
office visits attributable to influenza B respiratory disease
persisting until 50–64 years of age.
Among 65+ year olds, in an average season there were
31,644,400 office visits for a respiratory illness (broadly de-
fined), of which 2.3 % (n = 721,110) (SD across seasons
350,749) were for respiratory disease attributable to influ-
enza (Table 2). While the estimated rates of influenza-
attributable office visits for respiratory disease were lower
in the elderly than in children, the number of office visits
in 65+ year olds exceeded those in infants 0–1 year of age
(Table 3). The estimated rate of influenza-attributable of-
fice visits for respiratory disease was 28 % higher in 75+
year olds than in 65–74 year olds (Table 3).
There was marked inter-seasonal variability in influenza
attributions for respiratory (broadly defined) office visits
overall, and in the predominant influenza type (Table 2).
The highest estimate of influenza-attributable office visits
in both databases was in 2007/08, and the lowest estimate
was in 2008/09). In these seasons, influenza-attributable
respiratory infection (broadly defined) represented 13 and
6 % of the burden of respiratory illness respectively among
0–64 year olds.
Respiratory illness due to influenza in people <65 years
was predominantly attributable to influenza A/H3N2 in
the 2001/02, 2003/04 and 2005/06 seasons, approximately
equally attributable to A/H3N2 and type B lineages in the
2004/05 season, and predominately to type B in the 2002/
03, 2007/08 and 2008/09 seasons. Influenza A/H1N1
dominated only in 2006/07, a season in which influenza B
also co-circulated (Table 4). The majority of influenza re-
spiratory disease in adults aged 65+ years was attributable
to influenza A, with A/H1N1 and A/H3N2 contributing
equally (Table 3).
The largest numbers of influenza-attributable office
visits was among school-age children (5–17 year olds) and
young adults (18–49 year olds), each accounting for nearly
40 % (or 5.6 million consultations in an average season,
SD across seasons 1.7 million) of the medically attended
burden of influenza in individuals <65 year olds in the US
(Table 3). Overall, 38 and 47 % of all influenza-associated
office visits for respiratory disease in these respective age
groups were attributable to influenza B. The other influ-
enza subtypes shared a lower but still comparable burden,
Table 2 Estimated counts of influenza-attributable office visits for respiratory (broadly defined), respiratory and cardiorespiratory
causes in the United States, 2001–02 through 2008–09
Respiratory (broad) Respiratory Cardiorespiratory
Season Estimate (95 % CI) Estimate (95 % CI) Estimate (95 % CI)
MarketScan Commercial Database, <65 year olds
2001–02 12,365,184 (11,665,801–13,064,541) 10,475,575 (9,816,954–11,134,170) 10,194,445 (9,522,888–10,866,003)
2002–03 16,803,325 (15,883,426−17,723,224) 14,701,362 (13,836,458–15,566,240) 14,554,184 (13,664,649–15,443,744)
2003–04 13,618,103 (12,767,860–14,468,321) 11,354,261 (10,556,090–12,152,431) 11,258,742 (10,426,957–12,090,553)
2004–05 15,814,272 (15,089,234–16,539,284) 13,605,842 (12,927,419–14,284,264) 13,643,186 (12,922,048–14,364,325)
2005–06 11,795,968 (11,243,720–12,348,242) 10,071,294 (9,555,005–10,587,610) 10,213,174 (9,660,795–10,765,500)
2006–07 14,628,435 (13,601,384–15,655,487) 12,634,875 (11,674,057–13,595,718) 12,989,309 (11,977,996–14,000,621)
2007–08 21,896,301 (20,932,203–22,860,399) 18,921,369 (18,020,955–19,821,782) 19,535,453 (18,554,039–20,516,840)
2008–09 8,683,598 (8,167,552–9,199,670) 7,535,656 (7,053,640–8,017,619) 7,780,771 (7,262,485–8,299,004)
Average 14,450,648 − 12,412,529 − 12,521,158 −
Std dev 3,931,783 − 3,447,860 − 3,578,048 −
MarketScan Medicare Supplemental Database, 65+ year olds
2006–07 708,335 (354,590–1,062,080) 615,166 (286,572–943,759) 265,729 (0–682,663)
2007–08 1,078,071 (535,820–1,620,322) 936,707 (432,929–1,440,484) 396,427 (0–1,026,793)
2008–09 376,923 (185,672–568,173) 327,184 (149,709–504,659) 132,283 (0–343,834)
Average 721,110 − 626,352 − 264,813 −
Std dev 350,749 − 304,915 − 132,074 −
<65 years olds: 2001–02 through 2008–09 seasons, MarketScan Commercial Database
65+ year olds: 2006–09 seasons, MarketScan Medicare Supplemental Database
Std dev = standard deviation, average =mean seasonal estimate
95 % CI = 95 % confidence intervals
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Table 3 Average seasonal model attributions (number and rate per 100,000 population) by influenza sub-type and age
Influenza A/H1N1 Influenza A/H3N2 Influenza B All influenza
Age
group
Rate SD N SD Rate SD N SD Rate SD N SD Rate SD N SD
Respiratory broad
0–1 1148 1292 92,543 104,232 4189 3220 334,583 255,510 1958 1263 157,391 101,799 7295 1933 584,517 155,296
2–4 2163 2353 257,345 279,828 5252 4017 619,022 470,595 2256 1473 267,541 173,631 9672 2312 1,143,907 273,448
5–17 2824 3010 1,517,946 1,618,530 3573 2771 1,914,587 1,481,878 3996 2592 2,145,385 1,391,299 10392 3093 5,577,918 1,667,267
18–49 438 468 590,623 630,727 1787 1399 2,402,020 1,875,906 1979 1282 2,666,447 1,727,718 4205 1274 5,659,089 1,720,149
50–64 55 60 28,749 31,093 1229 957 608,283 458,111 1649 1072 848,186 556,510 2933 1031 1,485,217 555,566
0–64 953 1020 2,487,205 2,658,483 2285 1781 5,878,493 4,539,150 2343 1519 6,084,951 3,940,675 5581 1496 14,450,648 3,931,783
65–74 654 334 130,668 62,250 596 722 119,328 145,317 424 189 85,381 37,417 1674 837 335,377 164,184
75+ 811 383 147,352 68,341 757 920 137,573 167,557 574 269 104,445 48,993 2142 1040 389,370 188,526
65+ 725 356 276,803 129,745 669 811 255,580 310,995 492 226 188,727 85,855 1887 929 721,110 350,749
Otitis media
0–1 976 1069 78,683 86,175 1594 1301 127,280 103,167 3884 2515 312,139 202,623 6455 2291 518,102 186,416
2–4 821 859 97,574 102,047 1492 1182 175,651 138,078 2627 1697 311,427 200,700 4939 1613 584,652 191,428
5–17 336 354 180,606 190,499 389 309 208,399 165,421 771 497 414,081 267,052 1496 547 803,086 294,139
18–49 32 34 42,940 45,757 48 37 64,380 50,103 111 72 149,756 97,400 191 74 257,076 100,433
50–64 10 11 5377 5685 18 14 8859 6695 55 36 28,401 18,981 83 37 42,637 20,350
0–64 155 164 405,177 428,584 227 182 584,566 462,874 468 303 1,215,805 785,121 851 301 2,205,547 787,106
65–74 6 2 1267 363 6 6 1102 1231 4 2 826 404 16 7 3195 1447
75+ 1 0 140 89 1 1 132 197 0 0 87 21 2 1 359 179
65+ 3 1 1196 520 3 3 1069 1336 2 1 730 271 8 4 2994 1437
<65 years olds: 2001–02 through 2008–09 seasons, MarketScan Commercial Database
65+ year olds: 2006–09 seasons, MarketScan Medicare Supplemental Database
SD standard deviation of the variability of the attributable burden between seasons, N number
Table 4 Estimated counts of influenza-attributable office visits for respiratory disease (broad) in the United States by influenza
subtype
Influenza A/H1N1 Influenza A/H3N2 Influenza B
Season Estimate (95 % CI) Estimate (95 % CI) Estimate (95 % CI)
MarketScan Commercial Database, <65 year olds
2001–02 244,346 (206,437–282,230) 9,591,775 (8,949,669–10,233,881) 2,529,062 (2,349,650–2,708,475)
2002–03 4,927,892 (4,226,578–5,629,206) 956,554 (873,630–1,039,452) 10,918,879 (10,010,801–11,826,957)
2003–04 2253 (1715–2791) 13,208,713 (12,356,831–14,060,570) 407,137 (377,772–436,527)
2004–05 26,162 (21,539–30,785) 7,662,099 (7,143,927–8,180,245) 8,126,011 (7,568,687–8,683,335)
2005–06 679,718 (551,518–807,891) 6,668,041 (6,246,233–7,089,875) 4,448,210 (4,124,428–4,771,991)
2006–07 7,070,007 (5,985,195–8,154,818) 1,809,498 (1,686,185–1,932,810) 5,748,931 (5,289,075–6,208,788)
2007–08 3,334,887 (2,864,430–3,805,317) 6,838,330 (6,349,764–7,326,895) 11,723,085 (10,930,663–12,515,507)
2008–09 3,612,374 (3,071,846–4,152,875) 292,933 (273,464–312,428) 4,778,291 (4,434,527–5,122,082)
Average 2,487,205 − 5,878,493 − 6,084,951 −
SD 2,658,483 − 4,539,150 − 3,940,675 −
<65 years olds: 2001–02 through 2008–09 seasons, MarketScan Commercial Database
95 % CI = 95 % confidence intervals, SD = standard deviation of the variability of the attributable burden between seasons, average =mean seasonal estimate
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with 27 and 34 % of the influenza-associated office visits
for respiratory disease by children 5–17 year olds attribut-
able to influenza A/H1N1 and A/H3N2, respectively.
In an average season we estimate that there were
2,205,547 office visits for influenza-attributable otitis
media, representing 10 % of all office visits for OM in
<65 year olds in the US. The highest rates of influenza-
attributable OM were in children (0–1 and 2–4 year olds)
with 50 % of all office visits for OM occurring in these age
groups combined (Table 3). There was more OM attrib-
uted to influenza B than A in all age groups (Fig. 2). As
expected, the burden of visits for OM was low in adults.
Control outcome
The burden of medically-attended urinary-tract infec-
tions attributed to influenza by the model was negligible.
Discussion
To the best of our knowledge, our study is among the
first to estimate the burden of outpatient visits attribut-
able to influenza in the US. Using a novel outcome (re-
spiratory disease broadly defined), the model attributed
seasonal means of 14,450,648 (SD 3,931,783) (<65 year
olds) and 721,110 (SD 350,749) (65+ year olds) office
visits to influenza for respiratory disease.
Children (0 to <18 years of age) have the highest rates
of medically-attended influenza as determined by the
model. This is consistent with previous studies showing
that children are responsible for most influenza-
attributed doctor visits in the US and UK [6, 8, 14], but
contrasts with results of Molinari et al. [15] who used a
probabilistic model and estimated 31.4 million out-
patient visits for influenza among all age groups in 2003,
with the highest number of consultations in 65+ year
olds. The discrepancy between these results compared
to our own and other studies probably reflects the lack
of precision associated with the probabilistic approach,
which relied on assumptions for influenza consultation
rates guided by published clinical trials or epidemio-
logical studies.
While young children and adolescents have the highest
rates of office visits for influenza attributable respiratory
infections, some other studies indicate that the elderly
exhibit the highest influenza-attributable hospitalisations
and mortality rates (Table 5).
Olson et al. [16] reported excess visits for “respiratory
and fever” syndrome in emergency departments in New
York City between 2001 and 2006. The burden of influ-
enza among children <2 and 2–4 years of age estimated
in the present study was higher than the range deter-
mined by Olson et al. for comparable years (range
6508–9633 visits per 100,000 population versus 540–
7710 visits per 100,000 population in <2 year olds, and
8226–11,959 versus 610–4790 per 100,000 population in
2–4 year olds, respectively), and was higher for other
comparable age groups. This difference might be ex-
pected if emergency department visits represent only a
fraction of office visits. In another study, Fowlkes et al.
[14] used 38 outpatient practices to estimate the inci-
dence of medically attended influenza at the community
level. Overall, our estimates were in reasonable agree-
ment with those published by Fowlkes et al. However,
that study was restricted to a single season (2009/10), in
which the influenza A/H1N1 pandemic strain vastly pre-
dominated in the US.
Two studies set in the UK assessed the burden of
influenza-attributable respiratory illness in primary care.
Our estimates are higher than those of Pitman et al. [6]
and Fleming et al. [8] for all comparable age groups. The
estimates of the burden of medically-attended influenza
produced by Pitman were restricted to a single season
(2002/03), which was a mixed A/H3N2 and B season.
Burden estimates produced using a single season can be
unstable and may be affected by a number of factors, in-
cluding random inter-seasonal variations in the number
of cases diagnosed with a respiratory disease as well as
changes in the type and severity of the predominant
Fig. 2 The percentage of the estimated burdens for respiratory and
otitis media outcomes attributed to influenza A and influenza B by
age group (mean across seasons, MarketScan Commercial database).
Footnote: The total number of office visits for each outcome was:
Respiratory disease (broadly defined) N = 115,605,186, Otitis
media N = 17,644,379
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circulating influenza strain. Wide disparity in the attrib-
utable influenza burden between European countries
was also noted by Paget et al. [17], who reported sea-
sonal averages for influenza-attributable influenza-like-
illness of between 0.4 and 18 % in individual countries
(Table 5). In view of the dissimilarities between
individual countries, which include differences in popu-
lation, viral circulation patterns, climatic conditions,
healthcare systems and patterns of healthcare utilisation
(especially costs and incentives for seeking care), close
agreement between studies conducted in the UK and the
present estimates would not be anticipated.
Table 5 Seasonal Influenza attributions (rate per 100,000 population) in selected studies conducted in the US and Europe
























Italy, 2003–2008 surveillance network 0–4 9229
5–17 8915
Netherlands 2002–2008 surveillance network 0–4 925
5–17 121


















US [24] 1993–2008 The Healthcare Cost and
Utilization Project






US [25] 1997–2007 National Center for
Health Statistics
All-cause deaths All 11.92
Respiratory deaths All 3.58











RCGP royal college of general practitioners, p–y person years
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The model attributed a large number of visits for OM
to influenza. As expected, the majority of the influenza-
attributable OM burden was in younger age groups. We
estimated that 10 % of all office visits for otitis media in
<65 year olds were attributable to influenza, and that
6 % of all 0–1 year olds attend for an influenza-
attributable otitis media office visit in an average season.
Among 0–1 year olds, the seasonal rate of office visits
for influenza-attributable OM was close to that of re-
spiratory disease (broadly defined), lending support to
the notion that otitis media is part of the primary symp-
tomatology of influenza in this age group, rather than a
complication of influenza [8]. Clinical trials have sug-
gested that influenza vaccination reduces OM in chil-
dren [18–20], although one trial conducted in young
children (6–24 months) showed no impact of influenza
vaccination on OM or on healthcare utilization, suggest-
ing a potential age-related impact on efficacy [21].
As is typical of influenza, the influenza-attributable
burden of physician office visits was highly strain and age
specific, and varied by season. The 2003/04 season was
characterised by a severe A/H3N2 epidemic, whereas a
negligible burden was observed in the immediately pre-
ceding season. The relative impact of influenza A/H1N1
was small in some seasons for most age groups, but A/
H1N1 particularly affected the young (those <18 year olds)
and the elderly (65+ year olds) in 2006/07. Influenza A/
H3N2 and B shared most of the burden in adults aged
18–64 years. Among older adults (65+), the attributed
burden of respiratory disease was highest for influenza A/
H1N1.. Influenza B caused more office visits for respira-
tory illness than either A/H1N1 or A/H3N2 in individuals
between 5 and 64 years of age. Influenza type B also
caused more OM than A/H1N1 and A/H3N2 combined
in all age groups <65 years.
Unexpectedly, the estimated burden of influenza B
among adult 50–64 year olds was higher than the burden
of influenza A/H1N1 and A/H3N2. Although possibly a
valid finding, this result is at odds with epidemiological
expectations from previous reports which have shown a
predominantly higher burden associated with influenza A/
H3N2 in adults. It is possible that the proportion of the at-
tributed burden of A/H3N2 in adults was lower than ex-
pected due to the higher temporal overlap between A/
H3N2 and influenza B virology peaks in some seasons,
undermining the model’s ability to appropriately allocate
burden to influenza A/H3N2 in such cases.
We optimized the ICD9-coded outcome definition for
respiratory illness. Our broader-than-usual definition of
a respiratory visit, which included all respiratory diagno-
sis codes plus fever, cough, abnormalities of breathing
and unspecified viral infections, was more sensitive than
respiratory disease codes alone while retaining good spe-
cificity. By contrast, cardio-respiratory visits yielded
fewer influenza-associated cases, possibly because this
outcome is likely too non-specific, or because individuals
with cardiorespiratory illness are more likely to be hospi-
talized and less likely to receive primary care.
We recognise several potential limitations of this study.
The US has no nationwide data available to study the out-
patient disease burden. We used a convenience sample
(MarketScan databases) which may be subject to un-
known biases and which we extrapolated to a national
level. We used two different datasets, which means that
the two sets of estimates should be compared cautiously.
The available time series for the Medicare database was
short (three seasons) requiring use of an aggregated influ-
enza term with distribution to each of the influenza types
based on the relative proportion of counts for each strain
within influenza-positive specimens. This assumed that
the temporal pattern of circulation of each influenza type
is the same, and these strains are equally likely to cause a
case of the disease outcome modelled. Our model also as-
sumed that the collection of viral data and the detection
of outcome events was homogeneous from season to sea-
son. This means that the proportion of viral circulation
captured, and the conditions under which it was captured,
remained the same in each season. We excluded cyclic
terms from the final model, and in so doing excluded a
seasonal baseline designed to control for unspecified sea-
sonal factors associated with increased morbidity. Al-
though similar in shape to the cyclic term, the RSV
virology series had a lower amplitude, and for older age
groups peaked earlier than the cyclic pattern associated
with the respiratory disease outcome series. As a conse-
quence, a larger fraction of the burden that would be
otherwise attributed to the cyclic component may have
been attributed to influenza. Overall attribution rates in
our study were significantly higher across age-groups
compared to models that incorporate cyclic terms, in
agreement with a prior study that presented results for
both model types [6], suggesting that we may have overes-
timated the influenza burden. In addition to producing
larger attribution rates for influenza, the exclusion of the
cyclic term increased estimates of the RSV attributable
burden. We did not assess autocorrelation, which could
influence the quality of the modelling approach. The OM
and respiratory illness burdens are not additive, and it is
likely that many patients with an OM also had a respira-
tory diagnosis. Finally, the model predicted increased visits
for respiratory disease in autumn in all of the age groups
studied. In the absence of virology results for this period,
we are unable to identify the cause of these autumnal
peaks, although others have identified increases in respira-
tory virus infections such as rhinovirus and asthma during
autumn in the northern hemisphere [22, 23]. Because a
direct comparison with equivalent studies is not possible,
the generality of the present findings remains to be
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determined. However, the observation that the present es-
timates were consistent with expected age-and outcome-
specific patterns long-established in the literature gives
confidence about these results.
Conclusion
The respiratory burden of medically-attended influenza
illness in the US is high, and is strain- and age-specific,
with considerable seasonal variation. Unexpectedly, influ-
enza B was attributed to more influenza-related office
visits during the study period than either influenza A/
H3N2 or A/H1N1. The highest rates of office visits attrib-
utable to influenza were among children. The burden of
influenza-attributable OM in young children is similar to
that of respiratory disease. This is one of few studies to
model statistically the respiratory burden of medically-
attended influenza illness in the US, and the contribution
of influenza-attributable otitis media to that burden.
Whether it is a primary symptom of influenza in children,
or a complication of influenza, OM is theoretically pre-
ventable by vaccination. Understanding all influenza-
related outcomes that contribute to the outpatient burden
is important in assessing the cost-benefit of influenza
vaccination programmes.
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